BEBT-109

BEBT-109 is a potent pan-mutant-selective EGFR inhibitor. BEBT-109 has improved pharmacokinetic properties. BEBT-109 can be used for multiple mutant-EGFR-driven non-small cell lung cancer (NSCLC) research[1].

Product Specifications

CAS Number

[2050906-40-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bebt-109.html

Concentration

10mM

Purity

98.72

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

C=CC(NC1=CC(NC2=NC=CC(N3C=CC4=NC(OC)=CC=C43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O

Molecular Formula

C27H32N8O3

Molecular Weight

516.59

Precautions

H302, H315, H319, H335

References & Citations

[1]Fan F, et al BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer. Transl Oncol. 2021 Feb;14 (2) :100961.